CDKN2A and melanoma: Until a few years ago, CDKN2A/ARF (cyclin dependent kinase inhibitor 2A) and its binding partner CDK4 (cyclin dependent kinase 4) were the only known melanoma-predisposition genes tested in clinical practice.